Recent Transactions

Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of  pharmaceutical solutions and diagnostic tests for rare diseases

Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital

Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS

Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America

Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions

Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio

Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc

Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)

Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs  

Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products. 

Advised T5 Data Centers, a leading national data center owner and operator, on the creation of a fully integrated platform with QuadReal Property Group to develop, acquire and operate data centers via a $1.0 billion investment from QuadReal

Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants

Advised the Special Committee of Brookfield Canada Office Properties, Canada’s pre-eminent office real estate investment trust, on its go private transaction with Brookfield Property Partners L.P.

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix

Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan

Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems

Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare

Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

Advised Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space

Advised the Special Transaction Committee of the Board of Morgans Hotel Group on the transfer of its ownership interests in Delano South Beach and The Light Group to The Yucaipa Companies in exchange for the cancellation of certain securities held by Yucaipa (debt, preferred stock and warrants) together with a $100 million rights offering backstopped by Yucaipa

Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company

Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals

Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery

Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company

Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer

Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems

Advised the Kogan Family on the sale of Oakland Mall, a regional shopping mall in Troy, Michigan anchored by JC Penney, Sears and Macy's

Provided oversight of the process and an informal second opinion to the senior management of Slough Estates plc

Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries

Advised Forest City Enterprises, Inc. on the restructuring of its business relationship with its New York City affiliate Forest City Ratner